RENDITATUG VIDETECAN
UNII 69HT9CGD58

Substance Identification & Data

This profile provides standardized clinical and technical data for Renditatug Videtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 69HT9CGD58.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3061807-12-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

69HT9CGD58

CAS Registry Number

3061807-12-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RENDITATUG VIDETECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

14029

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Renditatug Videtecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Renditatug Videtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Renditatug Videtecan

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-451) [VH (Homo sapiens IGHV7-4-1*02 (85.7%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-9*03 (84.3%) -IGKJ4*01 (91.7%) G120>A (100'), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (230-230":233-233")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa ubstituted at the sulfur atoms of an average of six L-cysteinyl residues among 224, 230, 233, 214', 224'', 230'', 233'' and 214''' with (3RS)-1-[(30S)-30-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]carbamoyl}-26,32-dioxo-2,5,8,11,14,17,20,23-octaoxa-27,31-diazatritriacontan-33-yl]-2,5-dioxopyrrolidin-3-yl (videtecan) groups

Immunoglobulin G1, anti-(human tumor-associated calcium signal transducer 2) (human-Mus musculus monoclonal BAT0806 γ1-chain), disulfide with human-Mus musculus monoclonal BAT0806 κ-chain, dimer, reduced, hexakis(thioether) with (2S)-2-[[2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)acetyl]amino]-4-(1-oxo-4,7,10,13,16,19,22,25-octaoxahexacos-1-yl)butanoyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-L-ornithinamide

immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2 (TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody, conjugated on an average of six cysteinyl residues to videtecan, comprising a linker and a camptothecin derivative (exatecan) (renditatug videtecan)

renditatug videtecan [INN]

External Clinical & Regulatory Resources

Previous UNII69HRT16MGP

Next UNII69I0776AQH